A Prospective Study Evaluating the Effects of SSRI Exposure on Cardiac Size and Function in Newborns

Abstract

Background:

Selective serotonin reuptake inhibitors (SSRIs) are antidepressants prescribed in 10% of pregnancies in the United States. We have previously shown in preclinical studies that sertraline exposure impacts cardiomyocyte development, leading to reductions in left ventricular size and cardiac function.

Objectives:

We hypothesized that in utero SSRI exposure will lead to reduced left ventricular dimensions and cardiac function on echocardiography immediately after birth.

Methods:

Twenty term infants with and twenty-one term infants without in utero exposure to SSRIs underwent echocardiograms to assess cardiac size and function. Exclusion criteria for infants included prematurity, small or large for gestational age, any respiratory or cardiovascular support needed after birth, and any major congenital malformation.

Results:

Infants exposed to in utero SSRIs had significantly reduced right ventricular dimensions in diastole [Control 1.0 (0.86, 1.20) cm, SSRI 0.89 (0.730, 1.05) cm, p=0.03], and left ventricular lengths in diastole and systole [Diastole: Control 3.4 (3.25, 3.65) cm, SSRI 3.25 (3.10, 3.45) cm, p=0.03; Systole: Control 2.9 (2.65, 3.05) cm, SSRI 2.6 (2.50, 2.85) cm, p=0.01]. No differences were observed in cardiac function. Importantly, there were no differences in maternal conditions or infant birth weight, body surface area, or gestational age.

Conclusions:

Our findings suggest an association between in utero exposure to SSRIs and ventricular size in infants. Given the increasing use of SSRIs during pregnancy and the importance of early life programming on future cardiovascular health, larger studies need to be completed to determine if in utero SSRI exposure impacts ventricular size.